Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2917-2923

  Gasparri, Anna ^a   Moro, Monica ^a   Curnis, Flavio ^a   Sacchi, Angelina ^a   Pagano, Stefano ^a   Veglia, Fabrizio ^a   Casorati, Giulia ^a   Siccardi, Antonio G ^a   Dellabona, Paolo ^a   Corti, Angelo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FIBROSARCOMA; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AVIDIN; BIOTINYLATION; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033564833     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Fiers, W. Biologic therapy with TNF: preclinical studies. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 295-327. Philadelphia: J. B. Lippincott Co., 1995.
2. Spriggs, D. R., and Yates, W. Cancer chemotherapy: experiences with TNF administration in humans. In: B. Beutler (ed.), Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, pp. 383-406. New York: Raven Press, 1992.
3. Lejeune, F. J. High dose recombinant tumour necrosis factor (rTNF α) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur. J. Cancer, 31A: 1009-1016, 1995.
4. Eggermont, A. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., and Lejeune, F. J. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol., 14: 2653-2665, 1996.
5. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon γ: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol., 14: 479-489, 1996.
6. Alexander, H. R., Jr., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol., 16: 1479-1489, 1998.
7. Rath, U., Kaufmann, M., Schmid, H., Hofmann, J., Wiedenmann, B., Kist, A., Kempeni, J., Schlick, E., Bastert, G., Kommerell, B., and Mannel, D. Effect of intraperitoneal recombinant human tumour necrosis factor a on malignant ascites. Eur. J. Cancer, 27: 121-125, 1991.
8. Sidhu, R. S., and Bollon, A. P. Tumor necrosis factor activities and cancer therapy: a perspective Pharmacol. Ther., 57: 79-128, 1993.
9. Hieber, U., and Heim, M. E. Tumor necrosis factor for the treatment of malignancies. Oncology, 51: 142-153, 1994.
10. Corti, A., and Marcucci, F. Tumour necrosis factor: strategies for improving the therapeutic index. J. Drug Targ., 5: 403-413, 1998.
11. Moro, M., Pelagi, M., Fulci, G., Paganelli, G., Dellabona, P., Casorati, G., Siccardi, A. G., and Corti, A. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor α. Cancer Res., 57: 1922-1928, 1997.
12. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., Siccardi, A. G., and Fazio, F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res., 51: 5960-5966, 1991.
13. Siccardi, A. G., Paganelli, G., Pontiroli, A. E., Pelagi, M., Magnani, P., Viale, G., Faglia, G., and Fazio, F. In vivo imaging of chromogranin A-positive tumours by three-step monoclonal antibody targeting. Eur. J. Nucl. Med., 23: 1455-1459, 1996.
14. Paganelli, G., Grana, C., Chinol, M., De Cicco, C., Cremonesi, M., Tarditi, L., Franceschini, R., Zoboli, S., De Braud, F., and Siccardi, A. G. Antibody-guided radiotherapy in malignant glioma patients with Y-90-biotin using a three-step pretargeting approach. In: Advances in the Application of Monoclonal Antibodies in Clinical Oncology, p. 36. Chania, Greece: The Thirteenth International Hammersmith Conference, 1996.
15. Paganelli, G., Stella, M., Zito, F., Magnani, P., De Nardi, P., Mangili, F., Baratti, D., Veglia, F., Di Carlo, V., Siccardi, A. G., and Fazio, F. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J. Nucl. Med., 35: 1970-1975, 1994.
16. Bersani, L., Colotta, F., and Mantovani, A. Involvement of tumour necrosis factor in monocyte-mediated rapid killing of actinomycin D-pretreated WEHI 164 sarcoma cells. Immunology, 59: 323-325, 1986.
17. Pennica, D., Hayflick, J. S., Bringman, T. S., Palladino, M. A., and Goeddel, D. V. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc. Natl Acad. Sci. USA, 82: 6060-6064, 1985.
18. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B., and Goeddel, D. V. Human tumor necrosis factor: precursor, structure, expression and homology to lymphotoxin. Nature (Lond.), 321: 724-729, 1984.
19. Corti, A., Gasparri, A., Sacchi, A., Curnis, F., Sangregorio, R., Colombo, B., Siccardi, A. G., and Magni, F. Tumor targeting with biotinylated tumor necrosis factor α: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells. Cancer Res., 58: 3866-3872, 1998.
20. Corti, A., Poiesi, C., Merli, S., and Cassani, G. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNF α-soluble TNF receptor (p55) complex dissociation during assay incubations. J. Immunol. Methods, 177: 191-198, 1994.
21. Tartaglia, L. A., Weber, R. F., Figari, I. S., Reynolds, C., Palladino, M. A., Jr., and Goeddel, D. V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA, 88: 9292-9296, 1991.
22. Palladino, M. A., Jr., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D., and Patton, J. S. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 138: 4023-4032, 1987.
23. Nawroth, P. P., and Stern, D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163: 740-745, 1986.
24. Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P. C., Pan, Y. C., Olander, J. V., Connolly, D. T., and Stern, D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med., 172: 1535-1545, 1990.
25. Clauss, M., Murray, J. C., Vianna, M., de Waal, R., Thurston, G., Nawroth, P., Gerlach, H., Bach, R., Familletti, P. C., and Stern, D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem., 265: 7078-7083, 1990.
26. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med., 4: 408-414, 1998.
27. Sung, C., and van Osdol, W. W. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J. Nucl. Med., 36: 867-876, 1995.
28. Wilbur, D. S., Stayton, P. S., To, R., Buhler, K. R., Klumb, L. A., Hamlin, D. K., Stray, J. E., and Vessella, R. L. Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconj. Chem., 9: 100-107, 1998.
29. Marshall, D., Pedley, R. B., Boden, J. A., Boden, R., and Begent, R. H. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br. J. Cancer, 69: 502-507, 1994.
30. Saga, T., Weinstein, J. N., Jeong, J. M., Heya, T., Lee, J. T., Le, N., Paik, C. H., Sung, C., and Neumann, R. D. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res., 54: 2160-2165, 1994.
31. 111In-DTPA-biotin. Nucl. Med. Biol., 25: 95-99, 1998.
32. Sharkey, R. M., Karacay, H., Griffiths, G. L., Behr, T. M., Blumenthal, R. D., Mattes, M. J., Hansen, H. J., and Goldenberg, D. M. Development of a streptavidin-anticarcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconj. Chem., 8: 595-604, 1997.
33. Yao, Z., Zhang, M., Sakahara, H., Saga, T., Arano, Y., and Konishi, J. Avidin targeting of intraperitoneal tumor xenografts. J. Natl. Cancer Inst., 90: 25-29, 1998.
34. Goodwin, D. A. Tumor pretargeting: almost the bottom line. J. Nucl. Med., 36: 876-879, 1995.
35. Shin, S. U., Wu, D., Ramanathan, R., Pardridge, W. M., and Morrison, S. L. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J. Immunol., 158: 4797-4804, 1997.
36. Kalofonos, H. P., Rusckowski, M., Siebecker, D. A., Sivolapenko, G. B., Snook, D., Lavender, J. P., Epenetos, A. A., and Hnatowich, D. J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J. Nucl. Med., 31: 1791-1796, 1990.
37. Paganelli, G., Magnani, P., Siccardi, A., and Fazio, F. Clinical application of the avidin-biotin system for tumor targeting. In: D. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 239-253. Boca Raton, FL: CRC Press, 1995.
38. Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., Zardi, L., and Winter, G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol., 15: 1271-1275, 1997.
39. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Washington DC), 279: 377-380, 1998.
40. Paganelli, G., Chinol, M., Maggiolo, M., Sidoli, A., Corti, A., Baroni, S., and Siccardi, A. G. The three-step pretargeting approach reduces the human antimouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur. J. Nucl. Med., 24: 350-351, 1997.
41. Liénard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor a in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
42. Posner, M., Liénard, D., Lejeume, F. J., Rosenfelder, D., and Kirkwood, J. M. Hypothermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic in transit melanoma. Proc. Am. Soc. Clin. Oncol., 13: 1351, 1994.
43. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P., and Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature (Lond.), 361: 266-269, 1993.